Literature DB >> 19536107

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

José Baselga1, Sandra M Swain.   

Abstract

Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody-chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2-ERBB3 dimers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19536107     DOI： 10.1038/nrc2656

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  131 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

2.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Authors:  Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula A Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

3.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors:  M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

4.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

5.  HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.

Authors:  Akira Hirata; Fumihito Hosoi; Miho Miyagawa; Shu-ichi Ueda; Seiji Naito; Teruhiko Fujii; Michihiko Kuwano; Mayumi Ono
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

6.  A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization.

Authors:  Jose Baselga
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

7.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.

Authors:  Mitchell B Berger; Jeannine M Mendrola; Mark A Lemmon
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

8.  A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.

Authors:  Kim Pedersen; Pier-Davide Angelini; Sirle Laos; Alba Bach-Faig; Matthew P Cunningham; Cristina Ferrer-Ramón; Antonio Luque-García; Jesús García-Castillo; Josep Lluis Parra-Palau; Maurizio Scaltriti; Santiago Ramón y Cajal; José Baselga; Joaquín Arribas
Journal:  Mol Cell Biol       Date:  2009-04-13       Impact factor: 4.272

9.  Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.

Authors:  Kazuko Sakai; Hideyuki Yokote; Kimiko Murakami-Murofushi; Tomohide Tamura; Nagahiro Saijo; Kazuto Nishio
Journal:  Cancer Sci       Date:  2007-07-11       Impact factor: 6.716

10.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

Authors:  J Baselga; L Norton; J Albanell; Y M Kim; J Mendelsohn
Journal:  Cancer Res       Date:  1998-07-01       Impact factor: 12.701
View more
  486 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Primary trastuzumab resistance: new tricks for an old drug.

Authors:  Jason A Wilken; Nita J Maihle
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

Review 3.  Targeted therapies for adrenocortical carcinoma: IGF and beyond.

Authors:  Michael J Demeure; Kimberly J Bussey; Lawrence S Kirschner
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

4.  Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.

Authors:  Sashikanth Banappagari; Miriam Corti; Seth Pincus; Seetharama Satyanarayanajois
Journal:  J Biomol Struct Dyn       Date:  2012-06-26

Review 5.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

Review 6.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 7.  The regulatory crosstalk between kinases and proteases in cancer.

Authors:  Carlos López-Otín; Tony Hunter
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

8.  S100A14, a member of the EF-hand calcium-binding proteins, is overexpressed in breast cancer and acts as a modulator of HER2 signaling.

Authors:  Chengshan Xu; Hongyan Chen; Xiang Wang; Jidong Gao; Yiqun Che; Yi Li; Fang Ding; Aiping Luo; Shuguang Zhang; Zhihua Liu
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

Review 9.  Phytochemicals: Current strategies for treating breast cancer.

Authors:  Bridg'ette B Israel; Syreeta L Tilghman; Kitani Parker-Lemieux; Florastina Payton-Stewart
Journal:  Oncol Lett       Date:  2018-03-20       Impact factor: 2.967

10.  Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations.

Authors:  Juan Felipe Franco-Gonzalez; Javier Ramos; Victor L Cruz; Javier Martínez-Salazar
Journal:  J Mol Model       Date:  2012-10-23       Impact factor: 1.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.